Invokana

In March of 2013 the Food and Drug Administration (FDA) approved Johnson & Johnson’s Invokana (canagliflozin). Invokana is a sodium-glucose co-transporter 2 (SGLT2) used in the treatment of Type II Diabetes. Invokana causes blood sugar to leave the body through urine.

In May of 2015, the FDA released a drug safety communication indicating Invokana and other SGLT2 inhibitors may cause a serious condition called ketoacidosis. Ketoacidosis occurs when that body produces too many acids called ketones.

Symptom of ketoacidosis include nausea, vomiting, difficulty breathing, confusion, abdominal pain, thirst or dry mouth, frequent urination, high blood sugar, and unusual fatigue.

Other SGLT2 inhibitors include: Farxiga, Xigduo, Jardiance, Glyxambi and Invokament. Please note Invokamet is a combination of Invokana and Metformin.

If you have been adversely affected by Invokana, you need to contact Law Offices of Gary Green today to discuss your legal options without obligation. Call us at 1-888-4GARYGREEN or email ggreen@gGreen.com.

Print Friendly